AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$STVN

FEDERICI WILLIAM J purchased $274K of STVN

FEDERICI WILLIAM J purchased 20,000 shares of Stevanato Group S.p.A. (STVN) at $13.72 ($0.27M total) on 2026-11-09.

Original reporting
SEC EDGAR · FEDERICI WILLIAM J
Published Nov 12, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$STVN
Bullish
medium confidence
Mentioned
$STVN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STVNBullishLow
01

Why it matters

While the transaction is modest, insider buying can be a positive signal for short‑term sentiment, though the scale limits market impact.

02

Market read

Primary insider purchase filing with limited material impact; useful for traders monitoring insider activity.

03

What to watch

Potential upcoming corporate actions or market conditions not disclosed could influence the significance of the buy.

Relevance 5/10Novelty 4/10Timing: same-day filing

Background

Stevanato Group is an Italian medical device manufacturer listed in the U.S. as an ADR (STVN). The filing reports a director's open‑market purchase.

Company-level read

Ticker impact

$STVNBullishMedium confidence
Context

Director William J. Federici purchased 20,000 shares for $274,400, increasing his stake to 46,991 shares.

Expected impact

likely slight upward pressure as the market prices in insider confidence

Evidence & confidence

Form 4 filing is a primary source; the transaction size is modest, so impact is limited but positive.

Market effects

Sector

Minimal effect on the medical device sector; insider activity is company‑specific.

Regional

No broader regional impact.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The purchase may be routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • company
    Stevanato Group S.p.A.

    Issuer of the Form 4 filing.

  • person
    William J. Federici

    Director of Stevanato Group who made the purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

STVN insider trading history →

Related articles

$STVNHighAI 8/10

Stevanato Group Q3 Earnings Call Highlights

Stevanato Group (STVN) expects 2027 revenue growth to moderate to low-single-digit due to GLP-1-related headwinds, but believes growth will normalize beyond 2027. The company reaffirmed its 2026 guidance, forecasting revenue of €1.26B-€1.28B and adjusted EBITDA of €335M-€345.2M. It is ramping up manufacturing investments and working on over 50 GLP-1-related programs with 30 global customers.

finance.yahoo.com
$STVNMed

Stevanato (STVN) Q3 2026 Earnings Call Transcript

Stevanato (STVN) reported Q3 2026 earnings, with non-GLP biologics revenue up 30% offsetting GLP-1 declines. Full-year non-GLP biologics revenue rose 13%. The company expects lower GLP volumes in 2027 but strong demand in non-GLP biologics. They are backfilling revenue and expanding production capacity. Engineering segment results were below expectations, but BDS segment performance will offset this.

finance.yahoo.com
$STVNMed

Stevanato Group SpA (STVN) (Q3 2026) Earnings Call Highlights: Revenue Climbs 8%

Stevanato Group SpA (STVN) reported Q3 2026 revenue growth of 8%, but expects lower GLP-1 volumes in 2027 from a single customer, moderating growth. Engineering segment revenue declined 12%, and gross profit margin decreased to 29.1%. The company backfilled most GLP-1 shortfall but expects validation delays. Non-GLP biologics grew 30% in Q3, driven by broad engagement and capacity investments. Alina pen injector and other delivery devices are in validation stages.

finance.yahoo.com
$STVNMed

Stevanato Group S.p.A. (STVN): Financial results for Q3 2026

Stevanato Group S.p.A. (STVN) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026 - The Company Maintains Fiscal Year 2026 Guidance - (PIOMBINO DESE, Italy) – November 3, 2026 – Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug de

SEC EDGAR 6-K
HighAI 8/10

Why is Stevanato stock plunging today?

Stevanato Group's stock fell 25.5% to $14.71 after reporting Q3 2026 revenue of €326.1M, up 8% YoY, beating estimates. However, the outlook for 2027 revenue growth was cut to low single digits due to reduced GLP-1-related volumes from a large customer, alarming investors. The company maintained its full-year 2026 revenue guidance of €1.26B to €1.28B.

investing.com